BACKGROUND: High fractional exhaled nitric oxide (FeNO) is an indicator of poor asthma control
In 2011, the American Thoracic Society (ATS) published clinical practice guidelines that recommended use of FeNO for a variety of reasons, including to assess asthma control. 5 In addition, FeNO has been shown to have clinical utility in supporting the diagnosis of asthma, 5 predicting risk of asthma onset, 6 and response to preventive therapy. 7 Multiple factors can impact airway inflammation, and therefore FeNO levels. These include weight status, tobacco smoke exposure, recent steroid use, and recent respiratory illness. 5 Historically, assessment of asthma control has been aided by clinical tools such as spirometry, 2 and/or patient report of signs/symptoms.
However, neither of these assessments, unlike FeNO, directly assess inflammation. 8 Within a clinical framework, FeNO levels are an additional indicator of asthma control to aid in the management of asthma.
The National Health and Nutrition Examination Survey (NHANES)
provides an opportunity to assess FeNO levels in a nationally representative sample of children and adolescents with asthma and to thereby add to the understanding of variation in FeNO levels among youth with asthma. In this study, we describe factors associated with high FeNO among youth with asthma and assess whether high FeNO levels are associated with measures of asthma control.
| MATERIALS AND METHODS

| Study design
The National Health and Nutrition Examination Survey (NHANES) is administered by the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC). NHANES is a continuous cross-sectional survey that obtains a nationally representative sample of the noninstitutionalized civilian US population via a stratified and multistage probability cluster design. We examined 2007-2012 data for children and adolescents with asthma aged [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] years. The examination response rates for this age group was between 74% and 85%. 9 
| FeNO measurement
FeNO concentration was measured in exhaled air prior to the spirometry exam. Measurements were determined using the NIOX MINO® (Aerocrine AB, Solna, Sweden), a hand-held nitric oxide
analyzer. Details for procedures on obtaining FeNO can be found elsewhere. 9, 11 The mean of two FeNO measurements was used as the main outcome variable. High FeNO for this analysis was defined using the ATS age-specific criteria: >50 ppb for adolescents aged [12] [13] [14] [15] [16] [17] [18] [19] years and >35 ppb for those aged 6-11 years. 5 Previous studies have produced race-specific FeNO reference values, 11 however, our analysis defined high FeNO based on published ATS clinical practice guidelines. 5 
| Categorization of study variables
The association between FeNO and demographic and environmental characteristics, in addition to asthma-related signs/symptoms, were examined.
Age group was categorized as 6-11 years and 12-19 years. Race/ Hispanic origin was based on the reported responses from participants, or their proxy, and categorized as NH white, NH black, Hispanic, and "other." The "other" category included Asians, results for whom are not separately reported because of insufficient sample sizes.
Family income-to-poverty ratio (FIPR) was calculated by dividing family income by the federal poverty threshold specific for family size. 9 Participants were categorized as low income if their FIPR was less than 1.85, a cut-point used to determine income eligibility for some federal programs, including reduced price school lunches.
12
Weight status was determined using BMI percentiles calculated from the 2000 CDC BMI-for-age growth charts 9 and categorized as:
<5th (underweight), ≥5th to <85th (normal weight), ≥85th to <95th (overweight), and ≥95th (obese). Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared rounded to one decimal place. 9 Height and weight were measured using standardized protocols. 9 Tobacco smoke exposure was examined in three categoriessmokers, home exposure, and no exposure. Smokers were defined as participants aged 12-19 years answering affirmative to smoking cigarettes, cigars, or pipes within the last 5 days or having serum cotinine levels >10 ng/mL, a level used to define smoking in previous studies. 13 Home exposure was defined by report of household members smoking inside the home. We also examined the association between FeNO and cotinine levels (using a cut-point of 0.05 ng/mL Given that prevalence of high FeNO was greater than 10%, odds ratios (OR) may overestimate the relative risk (RR). 19 To investigate the differences between OR and RR, we used SUDAAN's PROC rlogist PREDMARG/adjrr statement. 10 Our assessment of RR found the association to be similar to that of the OR. The largest difference was in comparing NH blacks to NH whites, where adjusted OR = 3.4 and adjusted RR = 2.6 (24% lower for RR). Therefore, we report the adjusted odds ratio.
| RESULTS
There were 716 eligible participants aged 6-19 years for our analysis ( For each of the wheezing-related symptom measures representing components of asthma control, there were no significant differences in the prevalence of high FeNO (Table 3) . For example, high
FeNO prevalence for participants with no medical visits and 2+ visits within the last 12 months was 15.3% and 18% (P = 0.5297), respectively. Similar results were observed after adjustment for underlying characteristics and other components of asthma control.
With regard to spirometry measures ( Persons with race/Hispanic origin classified as "other" and BMI classified as "underweight" were included in overall estimates but not separately reported due to insufficient sample size. FeNO levels. 23 Differences in the sample population and methods of obtaining FeNO values could account for these different findings.
Differences between our study and previous studies in ascertainment of exposure variables may also account for some differences.
Participants who smoked or with home exposure to tobacco smoke had lower prevalence of high FeNO than those with no tobacco exposure. While this finding may be secondary to a physiologic etiology, 26 there is also a possibility of selection bias, where families with youth with higher severity of asthma go to greater lengths to eliminate any ETS exposure. 27 The association of asthma and obesity was summarized by a 2010 ATS Workshop statement. 28 There is evidence that obesity is a risk factor for asthma 28 as well as a possible risk factor for poor asthma control. 29 Few studies examining FeNO level as a concomitant biomarker have been conducted. A Hong Kong study investigating youth with asthma did not show any FeNO differences between the obese and non-obese. 30 However, this study used the Hong Kong
Growth Survey definition of obesity of >120% of median weight for height, which has been shown to classify a greater proportion of children as obese when compared to World Health Organization and CDC obesity definitions using BMI percentile. 31 A study found that overweight/obese children with low FeNO were more likely to have asthma. 32 We found that participants classified as obese have lower prevalence of high FeNO when compared to those with normal weight.
NAEPP guidelines recommend use of spirometry to aid in the assessment of asthma control. 2 ATS guidelines recommend measuring airway inflammation with FeNO to help determine asthma control and management. 5 We found a low agreement 33 between abnormal FeNO and spirometry, results that are consistent with a previous study. by patients and caregivers. 34 We analyzed similar wheezing-related respiratory symptoms, although the time frame of recall differs, 34 
